1. Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, China. 2. Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, Henan, China. 3. Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. *These authors contributed equally to this article.
✉ Corresponding author: Medical Research Center, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou, 450052, Henan, China. Telephone: + 86-371-66913632; Fax: + 86-371-66913632; E-mail: zhihaiac.cn (Zhihai Qin), fazhanwang_20edu.cn (Fazhan Wang).More
Citation:
Zhang L, Zhu L, Yao X, Lou X, Wan J, Duan X, Pan L, Li A, Gu Z, Wang M, Wang F, Qin Z. Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis. Int J Biol Sci 2022; 18(4):1476-1490. doi:10.7150/ijbs.67138. https://www.ijbs.com/v18p1476.htm
Chemotherapeutic drugs have been successfully used to treat several cancers, including melanoma. However, metastasis occasionally occurs after chemotherapy. Here, we reported that paclitaxel (PTX) treatment for B16F10 tumour in mice led to an enhanced lymphatic metastasis of the melanoma cells, although a significant inhibition of tumour growth at the injection site was observed. Further study demonstrated that PTX upregulated the expression of C-C chemokine receptor type 7 (CCR7) in B16F10 cells, enhancing their migration through the activation of JNK and p38 signalling pathways. Loss of CCR7 or blockade of C-C motif chemokine ligand 21 (CCL21)/CCR7 axis abolished the pro-migration effect of PTX on B16F10 melanoma cells. Importantly, combination of PTX and CCR7 mAb could simultaneously delay the tumour growth and reduce the lymphatic metastasis in B16F10 melanoma. The blockade of CCL21/CCR7 axis may collectively serve as a strategy for lymphatic metastasis in some melanoma after chemotherapy.
Zhang, L., Zhu, L., Yao, X., Lou, X., Wan, J., Duan, X., Pan, L., Li, A., Gu, Z., Wang, M., Wang, F., Qin, Z. (2022). Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis. International Journal of Biological Sciences, 18(4), 1476-1490. https://doi.org/10.7150/ijbs.67138.
ACS
Zhang, L.; Zhu, L.; Yao, X.; Lou, X.; Wan, J.; Duan, X.; Pan, L.; Li, A.; Gu, Z.; Wang, M.; Wang, F.; Qin, Z. Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis. Int. J. Biol. Sci. 2022, 18 (4), 1476-1490. DOI: 10.7150/ijbs.67138.
NLM
Zhang L, Zhu L, Yao X, Lou X, Wan J, Duan X, Pan L, Li A, Gu Z, Wang M, Wang F, Qin Z. Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis. Int J Biol Sci 2022; 18(4):1476-1490. doi:10.7150/ijbs.67138. https://www.ijbs.com/v18p1476.htm
CSE
Zhang L, Zhu L, Yao X, Lou X, Wan J, Duan X, Pan L, Li A, Gu Z, Wang M, Wang F, Qin Z. 2022. Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21/CCR7 axis. Int J Biol Sci. 18(4):1476-1490.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.